INTS实时信号 | 通过Getagraph.com最大化利润

购买 110716 min ago

@ $3.41

发出时间: 13 Feb 2024 @ 03:19

回报率: 15.25%

上一信号: Feb 9 - 01:41

上一信号: 出售

回报率: -5.28 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:28):

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors...

Stats
今日成交量	8 957.00
平均成交量	50 140.00
市值	53.88M
EPS	$0 ( 2024-04-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.85
ATR14	$0.0460 (1.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Wesolowski John M	Buy	25 000	Stock Option (right to buy Common Stock)
2024-03-06	Leahy Emer	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Goldberg Mark A	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Donovan Daniel	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Bender Lewis H	Buy	464 805	Stock Option (right to buy Common Stock)

INSIDER POWER
57.13
Last 23 transactions
Buy: 803 379 \| Sell: 331 500

Intensity Therapeutics, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Intensity Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2023
营收:	$0
毛利润:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2022
营收:	$0
毛利润:	$-179 037 (0.00 %)
EPS:	$-0.570

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.439

Financial Reports:

No articles found.

Intensity Therapeutics,

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.